cancers-logo

Journal Browser

Journal Browser

Advances in the Management of Peritoneal Surface Malignancies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (15 March 2025) | Viewed by 6023

Special Issue Editor


E-Mail Website
Guest Editor
Peritoneal Surface Malignancy Program, Division of Surgical Oncology, Department of Surgery, The University of Kansas Health System, Kansas City, MO 66160, USA
Interests: oncologic surgery; gastrointestinal cancers; peritoneal surface malignancies; cytoreductive surgery; heated intraperitoneal chemotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Peritoneal surface malignancies, whether primary or secondary, continue to be difficult to manage. Despite the fact that there have been significant successes in the treatment of hematologic-based metastases, the peritoneum surface remains relatively elusive due to a blood–peritoneal barrier. However, in combination with effective systemic therapies, progress has been made with the addition of cytoreductive surgery and hyperthermic intraperitoneal therapy (CRS-HIPEC). In the case of colorectal cancer, patients with isolated metastatic peritoneal carcinomatosis can now achieve a survival rate of 40–50% in select patients who receive systemic therapy combined with CRS-HIPEC; this is similar to the survival of patients with isolated liver metastases.

The utilization of CRS-HIPEC remains controversial in some cases due to a lack of level one evidence showing a survival benefit for some primary disease sites. Cytoreductive surgery alone, especially when all gross disease is removed, consistently shows a survival advantage in the multimodality treatment of peritoneal carcinomatosis for many disease sites. However, the addition of hyperthermic intraperitoneal chemotherapy has been questioned as providing a survival advantage. Interestingly, in peritoneal carcinomatosis from ovarian cancer, the addition of hyperthermic intraperitoneal chemotherapy to cytoreductive surgery has consistently shown an inherent survival value in several large randomized prospective surgery studies despite this disease having only recently been studied for this approach.

The multimodality management of peritoneal surface malignancies remains in its infancy. Multiple variables require further research, and more clinical trials are needed. The use of CRS-HIPEC needs to become more standardized before it is universally accepted as an integral component in managing peritoneal surface malignancies from specific primary sites of origin. Important topics need to be addressed such as appropriate patient selection, including patient and tumor molecular correlates, that can lead to individualized care. Furthermore, the standardization of CRS-HPEC techniques needs to be fine-tuned, including delivery systems, agents, dosages, length of HIPEC administration, and temperatures. Importantly, ideal sequencing of CRS-HIPEC with systemic therapy needs to be established.

This Special Issue of Cancers aims to include original studies and reviews of the important topics in peritoneal surface malignancies and their treatment, including CRS-HIPEC and systemic therapy. The integration of surgery, systemic therapy, and other modalities will require cooperation between the various types of providers. Many in the field have strong opinions about the management of peritoneal surface malignancies, which could hinder progress. Providers in several fields need to remain open-minded. Finally, several studies have shown that only institutions with the appropriate resources and volume of cases should take on the more complex cases of peritoneal surface malignancies.

Prof. Dr. Mazin Al-Kasspooles
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • peritoneal surface malignancies
  • cytoreductive surgery
  • hyperthermic intraperitoneal therapy
  • systemic therapy
  • multimodality management

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (7 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 2053 KiB  
Article
Advancing Treatment Outcomes for Peritoneal Surface Malignancies in Low- and Middle-Income Countries: Insights from the First Multicenter Study in North Africa
by Amine Souadka, Hajar Habbat, Amin Makni, Mourad Abid, Zakaria El Mouatassim, Amin Daghfous, Zakia Korjani, Wael Rebai, Mouna Ayadi, Wafa Hania Messai, Mohammed Anass Majbar, Amine Benkabbou, Raouf Mohsine and Abdelilah Souadka
Cancers 2025, 17(13), 2113; https://doi.org/10.3390/cancers17132113 - 24 Jun 2025
Abstract
Background: Peritoneal surface malignancies (PSM) are aggressive cancers with limited treatment access in low- and middle-income countries (LMICs). While cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have improved survival outcomes globally, their feasibility in LMICs remains underexplored. This first multicenter study in [...] Read more.
Background: Peritoneal surface malignancies (PSM) are aggressive cancers with limited treatment access in low- and middle-income countries (LMICs). While cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have improved survival outcomes globally, their feasibility in LMICs remains underexplored. This first multicenter study in North Africa evaluates the implementation and outcomes of CRS with or without HIPEC in resource-limited settings. Methods: A retrospective cohort study of 391 patients with PSM (colorectal cancer, pseudomyxoma peritonei, ovarian cancer, gastric cancer, or mesothelioma) treated with CRS ± HIPEC between 2014 and 2020 at four tertiary centers in Morocco, Tunisia, and Algeria. Primary outcomes included overall survival (OS), disease-free survival (DFS), and severe postoperative morbidity (Clavien-Dindo ≥ IIIa). Cox regression was used to identify independent prognostic factors. Results: Among 391 patients, complete cytoreduction (CC-0/1) was achieved in 88%, and HIPEC was performed in 39%. Severe morbidity occurred in 22%, with HIPEC, spleno-pancreatectomy, and incomplete cytoreduction (CC-2) identified as significant risk factors. The median OS was 68 months, with 1- and 5-year survival rates of 97% and 56%, respectively. Patients undergoing CRS + HIPEC had significantly longer OS than CRS alone (70 vs. 64 months, p = 0.016), though DFS was not significantly different between groups. Independent predictors of improved OS included HIPEC, CC score, PCI, and primary tumor type. Conclusions: This first North African multicenter study establishes the feasibility and efficacy of CRS and HIPEC in LMICs, achieving survival outcomes comparable to high-income settings. The findings support expanding advanced PSM treatment programs in resource-limited settings, emphasizing structured training and multidisciplinary collaboration to improve access and outcomes. Full article
(This article belongs to the Special Issue Advances in the Management of Peritoneal Surface Malignancies)
Show Figures

Figure 1

15 pages, 1196 KiB  
Article
Iterative Cytoreductive Surgery and HIPEC for Peritoneal Metastases from Primary Appendiceal and Colorectal Cancers: An Observational Study
by Andrew M. Fleming, Owen M. Clark, Jaewon J. Lee, Kristen Dougherty, Leah E. Hendrick, Jordan Raine, Ian Solsky, Paxton V. Dickson, Evan S. Glazer, David Shibata, Elizabeth Gleeson, Gitonga Munene and Jeremiah L. Deneve
Cancers 2025, 17(12), 2014; https://doi.org/10.3390/cancers17122014 - 17 Jun 2025
Viewed by 64
Abstract
Background: Peritoneal relapse after cytoreduction and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is common. Repeat CRS/HIPEC offers the potential for long-term survival in the appropriately selected patient. Methods: We performed a retrospective review of a single institution database to assess perioperative outcomes after [...] Read more.
Background: Peritoneal relapse after cytoreduction and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is common. Repeat CRS/HIPEC offers the potential for long-term survival in the appropriately selected patient. Methods: We performed a retrospective review of a single institution database to assess perioperative outcomes after repeat CRS/HIPEC for appendiceal (pAC) and colorectal (pCRC) cancers. Kaplan–Meier and Cox estimates were used to assess survival. Results: Of 157 patients, 103 patients underwent initial CRS/HIPEC for pAC (n = 67) or pCRC (n = 36) histologies. Twenty-seven pAC patients (27/67, 40%) and 23/36 pCRC patients (63%) developed disease recurrence. Relapsed patients had a higher burden of disease (PCI), operative length and blood loss and received adjuvant chemotherapy (all p < 0.05). Nine of the 27 relapsed pAC patients and 5 of the 13 relapsed pCRC patients underwent repeat CRS/HIPEC. The median time to repeat CRS/HIPEC was 18 months (4–26 months), and a CCR-0 and CCR-1 were achieved in 79% and 21%, respectively. The 1-, 3- and 5-year OS for pAC patients who underwent repeat CRS/HIPEC was 88.9%, 88.9% and 77.8%, and the 1- and 3-year OS for pCRC patients was 100% and 25%, respectively. Repeat CRS/HIPEC for pAC was associated with significant improvement in OS (p = 0.03), while for pCRC, no significant difference was observed (p = 0.99). Conclusions: Repeat CRS/HIPEC for isolated peritoneal recurrence is safe and offers the potential for long-term survival. Patient selection is key to ensure optimal cytoreduction when considering repeat CRS/HIPEC. Full article
(This article belongs to the Special Issue Advances in the Management of Peritoneal Surface Malignancies)
Show Figures

Figure 1

13 pages, 4535 KiB  
Article
Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Malignancies with Palliative and Bidirectional Intent
by Daniele Marrelli, Ludovico Carbone, Daniele Fusario, Roberto Petrioli, Gianmario Edoardo Poto, Giulia Grassi, Riccardo Piagnerelli, Stefania Angela Piccioni, Carmelo Ricci, Maria Teresa Bianco, Maria Antonietta Mazzei, Stefano Lazzi and Franco Roviello
Cancers 2025, 17(12), 1938; https://doi.org/10.3390/cancers17121938 - 11 Jun 2025
Viewed by 306
Abstract
Background: PIPAC is an innovative treatment that delivers low-dose aerosolized chemotherapy into the abdominal cavity of patients with peritoneal surface malignancies (PSMs). However, its role in the multimodal management of PSMs is unclear. Methods: We retrospectively analyzed data from 64 patients [...] Read more.
Background: PIPAC is an innovative treatment that delivers low-dose aerosolized chemotherapy into the abdominal cavity of patients with peritoneal surface malignancies (PSMs). However, its role in the multimodal management of PSMs is unclear. Methods: We retrospectively analyzed data from 64 patients who underwent PIPAC for PSMs of a primary or secondary origin between June 2020 and December 2024 (median age of 64 years). Primary tumor sites included gastric (42.2%), colorectal (23.4%), ovarian cancer (21.9%), and others (12.5%). The median PCI was 15 (IQR 9–25), with ascites present in 60.9% of cases and a positive cytology in 48.4%. Results: A total of 82 PIPAC sessions were performed in 64 patients. The mean operation time was 96 min. Severe adverse events, defined as the Common Terminology Criteria for Adverse Events (CTCAE) of a grade ≥ 2, occurred in four patients (6.2%). The median hospital stay was 3 days, and systemic chemotherapy was resumed within 14 days after the procedure in 27 patients. Among the entire cohort, 37.5% received bidirectional therapy and 62.5% received palliative treatment, with a lower peritoneal cancer index (PCI) in the bidirectional group (9.5 vs. 23). The median overall survival (OS) was 32 months from diagnosis. Sixteen patients (25%) underwent two or more PIPAC sessions and showed an advantage in survival compared to patients who underwent only one procedure (3-year OS: 63.2% vs. 38.4%, p 0.030). Conversion surgery was achieved in 34.4%. Patients treated with a bidirectional intent demonstrated a longer OS (3-year: 66.0% vs. 33.9%, p 0.011). Colorectal and ovarian tumors exhibited better long-term outcomes compared to gastric cancer. Conclusions: PIPAC is a promising treatment for PSMs, with a low morbidity rate. Its favorable safety and short interval to systemic therapy resumption support its use as part of a bidirectional strategy. Full article
(This article belongs to the Special Issue Advances in the Management of Peritoneal Surface Malignancies)
Show Figures

Figure 1

15 pages, 1014 KiB  
Article
Clinical and Pathological Risk Factors for Peritoneal Metastases in a Surgical Series of T4 Colorectal Cancers
by Dario Baratti, Carlo Galdino Riva, Marcello Guaglio, Tommaso Cavalleri, Gaia Colletti, Shigeki Kusamura, Giovanna Sabella, Massimo Milione, Elisabetta Kuhn, Francesca Laura Nava and Marcello Deraco
Cancers 2025, 17(7), 1103; https://doi.org/10.3390/cancers17071103 - 25 Mar 2025
Viewed by 510
Abstract
Background: T4 colorectal cancer (CRC) is associated with an increased risk of peritoneal metastases (PM), but it is currently not possible to accurately predict which patients with T4 CRC develop PM. We investigated the occurrence and risk factors for PM in these patients. [...] Read more.
Background: T4 colorectal cancer (CRC) is associated with an increased risk of peritoneal metastases (PM), but it is currently not possible to accurately predict which patients with T4 CRC develop PM. We investigated the occurrence and risk factors for PM in these patients. Methods: A mono-institutional prospective database of 352 patients undergoing T4 primary CRC resection from 2012 to 2021 was reviewed. Clinico-pathological variables potentially associated with synchronous or metachronous PM were tested by univariate and multivariate analyses. Results: The prevalence of synchronous PM was 73/352 (20.7%) and was significantly associated with age (p = 0.037), primary site (p = 0.002), positive nodes (p = 0.005), elevated CA19.9 (p = 0.001), and non-intestinal histology (p = 0.001). After a median follow-up of 35.9 months (95% confidence interval [CI] = 29.5–44.9), metachronous CRC-PM occurred in 36/164 patients (22.0%) with available data, accounting for a three-year cumulative incidence of 21.5% (95% CI = 14.3–28.1). Metachronous CRC-PM occurred in 3/48 patients (6.2%) with negative nodes and normal CEA, as compared with 33/116 patients (28.4%) with positive nodes and/or elevated CEA (p < 0.001). Combined nodal and CEA status (hazard ratio [HR] = 1.27; 95% CI = 1.02–1.59; p = 0.033), postoperative chemotherapy (HR= 0.51; 95% CI = 0.33–0.77; p = 0.001), and positive resection margins (HR = 2.01; 95% CI = 1.20–3.39; p = 0.008) were significantly associated with PM. Conclusions: The peritoneum is a major site for treatment failure in T4 CRC. Patients with normal CEA and negative lymph nodes are associated with a significantly lower risk for metachronous CRC-PM. These findings may help in refining patient selection for integrated approaches aiming at the prevention or early treatment of CRC-PM, which are pending validation in prospective studies. Full article
(This article belongs to the Special Issue Advances in the Management of Peritoneal Surface Malignancies)
Show Figures

Figure 1

20 pages, 1594 KiB  
Article
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS): Age-Related Outcomes and a Look into the Future
by Salvador Aguirre, Jill K. Haley, Julie A. Broski, Jordan Baker, Luke V. Selby, Shahid Umar and Mazin F. Al-Kasspooles
Cancers 2025, 17(3), 486; https://doi.org/10.3390/cancers17030486 - 1 Feb 2025
Viewed by 1273
Abstract
Introduction: Peritoneal carcinomatosis presents significant treatment challenges. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers a promising therapeutic approach. Patient selection remains critical, and the role of age as an exclusion criterion requires further investigation. This study evaluates whether age influences postoperative [...] Read more.
Introduction: Peritoneal carcinomatosis presents significant treatment challenges. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers a promising therapeutic approach. Patient selection remains critical, and the role of age as an exclusion criterion requires further investigation. This study evaluates whether age influences postoperative outcomes in CRS-HIPEC patients. Methods: A retrospective review of a prospective comprehensive database of 271 CRS-HIPEC procedures performed between 2018 and 2023 was conducted. Logistic regression assessed the relationship between age and postoperative outcomes. Age groups (18–44, 45–69, ≥70 years) were compared based on demographic data, primary tumor site, Peritoneal Cancer Index scores, and key outcome measures. Results: Across the different age groups, there were no significant differences in PCI scores, recurrence, disease-free survival, 30-day morbidity, or mortality. Length of stay was longer in older patients (p = 0.009). Patients aged ≥70 had higher readmission rates (p = 0.041) and were more often discharged to transitional care facilities (p = 0.001). Older patients were also more likely to experience Clavien–Dindo grade III or higher complications (p = 0.008). Logistic regression confirmed these findings. Continuous age analysis yielded similar results and revealed significant differences in race and primary organ involvement. Conclusions: Age is not a significant predictor of 30-day morbidity, mortality, or survival outcomes in patients undergoing CRS-HIPEC. However, older patients require closer attention to discharge planning and readmission risk management. This study highlights the importance of comprehensive patient assessment beyond age and underscores the need for further research to better understand factors influencing outcomes in this population. Full article
(This article belongs to the Special Issue Advances in the Management of Peritoneal Surface Malignancies)
Show Figures

Figure 1

10 pages, 241 KiB  
Article
Safety and Efficacy of Initiating Parenteral Nutrition at Home, Home Start PN, in Advanced Peritoneal Metastasis
by Chunmeng Zhang, Ujwal Yanala, Mounika Addula, Sherry Adams, Louise Ocken, Patricia Skiendziel, Tia Bodkins and Jason M. Foster
Cancers 2024, 16(24), 4272; https://doi.org/10.3390/cancers16244272 - 23 Dec 2024
Viewed by 1042
Abstract
Background: Patients with peritoneal carcinomatosis often experience intestinal failure throughout the course of their disease, and total parenteral nutrition (TPN) can be used as a temporary solution or as a bridge to definitive cytoreductive surgery. Guidelines for TPN are well established for inpatients [...] Read more.
Background: Patients with peritoneal carcinomatosis often experience intestinal failure throughout the course of their disease, and total parenteral nutrition (TPN) can be used as a temporary solution or as a bridge to definitive cytoreductive surgery. Guidelines for TPN are well established for inpatients and in 2014, guidelines were established for the initiation of TPN for outpatients in a home setting. However, the safety and efficacy of home start TPN in advanced oncology patients remain unknown. This study aims to explore the safety and efficacy of starting TPN in the home setting for patients with peritoneal carcinomatosis. Method: Health records of advanced cancer patients receiving TPN during 2009–2020 were retrospectively reviewed. Data pertaining to diagnosis, demographics, nutritional parameters, and outcomes including hospital readmission rates were collected. Safety was measured based on catheter-related complications and hospital admissions related to electrolyte or fluid imbalance due to TPN. Efficacy was determined by weight gain/stability and pre-albumin and albumin levels. The Fisher’s exact and Kruskal–Wallis tests were used to analyze the data. Results: Seventy TPN patients were identified, of which forty-two were home start (HS) and twenty-eight were in hospital (HP). The two groups were not significantly different in age, (HS: mean = 58.3 ± 13.9; HP: mean = 58.0 ± 13; p = 0.95), baseline body weight (p = 0.13), baseline albumin (p = 0.26) or pre-albumin (p = 0.48). At the end of treatment, the HS and HP groups had similar percentages of patients experiencing weight gain/stability (75% vs. 47%, p = 0.1), stable/increased pre-albumin (68% vs. 65%, p = 1), and stable/increased albumin levels (48% vs. 59%, p = 0.58). There was no difference in observed readmission between the groups (p = 0.79). At the end of treatment, 48% of the HS group and 36% of the HP group resumed an oral diet. Conclusions: This is the first study to present a comparison between home and hospital start TPN in advanced cancer patients, demonstrating that the initiation of outpatient TPN in the home setting is as safe and efficacious as TPN initiated in the hospital. Full article
(This article belongs to the Special Issue Advances in the Management of Peritoneal Surface Malignancies)

Review

Jump to: Research

15 pages, 951 KiB  
Review
Iterative Intraperitoneal Chemotherapy in Gastric Cancer Peritoneal Carcinomatosis
by Fatemeh Tajik, Belain Eyob, Aaqil M. Khan, Vinodh Kumar Radhakrishnan and Maheswari Senthil
Cancers 2025, 17(2), 289; https://doi.org/10.3390/cancers17020289 - 17 Jan 2025
Viewed by 1686
Abstract
Background/objectives: Despite the incremental improvement of survival with systemic therapy in metastatic gastric cancer (GC), the outcomes of patients with peritoneal carcinomatosis (PC) remain poor. The limited effectiveness of systemic therapy is attributed to the blood–peritoneal barrier and anarchic intra-tumoral circulation, which reduce [...] Read more.
Background/objectives: Despite the incremental improvement of survival with systemic therapy in metastatic gastric cancer (GC), the outcomes of patients with peritoneal carcinomatosis (PC) remain poor. The limited effectiveness of systemic therapy is attributed to the blood–peritoneal barrier and anarchic intra-tumoral circulation, which reduce the penetration of systemic therapy. Approaches that incorporate intraperitoneal (IP) chemotherapy, in addition to systemic therapies, may be a viable alternate strategy. Therefore, we provide a review of biology of gastric cancer peritoneal metastasis and evidence for bidirectional iterative IP chemotherapy in GCPC. Methods: A comprehensive search in PubMed, Scopus, Embase, Web of Science, Google Scholar, and ClinicalTrials.gov was performed to find the relevant articles and ongoing phase II/III clinical trials in iterative IP chemotherapy in GCPC. Results: Intraperitoneal (IP) chemotherapy leverages the blood–peritoneal barrier to allow for the administration of high concentrations of chemotherapy directly to the peritoneal metastases, with a significant reduction in the systemic toxicity and enhanced drug efficacy against peritoneal metastasis. This pharmacokinetic advantage of IP chemotherapy can be further enhanced by additional measures such as heat or aerosolization. There are three IP chemotherapy approaches, namely, heated intraperitoneal chemotherapy (HIPEC), pressurized intraperitoneal aerosolized chemotherapy (PIPAC), and normothermic intraperitoneal chemotherapy (NIPEC). Recent evidence suggests that iterative IP chemotherapy combined with systemic therapy may offer significant survival benefits for patients with peritoneal metastasis. Furthermore, bidirectional treatment approaches may also increase the chances of surgical resection and survival. Conclusions: IP chemotherapy plays a pivotal role in the management of gastric carcinomatosis, particularly in combination with cytoreduction in highly selected patients. The combination of systemic and regional control may increase the chances of surgical resection and may ultimately lead to significant survival benefits. Full article
(This article belongs to the Special Issue Advances in the Management of Peritoneal Surface Malignancies)
Show Figures

Figure 1

Back to TopTop